Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,577 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07022587Recruiting
Dissolving stent with drug for blocked heart arteries
This trial tests a stent that slowly dissolves after opening a blocked heart artery, releasing a drug to prevent reclogging. It may help people with narrowing in one or two spots that are not too hard or twisted.
Xi'an, ShannxiAges 18–75 - NCT07021040Recruiting
Nasal biopsy study for Alzheimer's and smell disorders
This study takes a small tissue sample from inside your nose to look for changes linked to Alzheimer's disease or smell problems. It may help us better understand how these conditions affect the brain.
Durham, North CarolinaAges 18 years+ - NCT07014293Recruiting
Building resilience in early lymphoma survivors
This study looks at ways to help people feel stronger and cope better after finishing lymphoma treatment. If your lymphoma is under control, you may join to learn skills that improve your emotional well-being.
Boston, MassachusettsAges 18 years+ - NCT07018518RecruitingPhase 1
Pin and immunotherapy combo for advanced liver cancer
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT07023588RecruitingPhase 2
Optimizing AML treatment based on early response
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Changchun, JilinAges 18 years+ - NCT06997055Recruiting
Study of Steqeyma® biosimilar in Crohn's and psoriasis
This study follows people with Crohn's disease or plaque psoriasis who are switching from the reference Ustekinumab to a biosimilar (Steqeyma®). It aims to see how well the biosimilar works in real-world settings.
AmiensAges 18 years+ - NCT02685969Recruiting
Brain scan study of amyloid and brain sugar use
This study uses brain imaging to measure two things in the brain—amyloid protein and how the brain uses sugar. It may help researchers better understand early brain changes in people in the ALFA project.
Barcelona, CataloniaAges 45–75 - NCT04664491Recruiting
Program to reduce COPD flare-ups with standardized care
This study tests whether a structured care program for COPD can lower how often your symptoms flare up. It may help by improving everyday management and preventing future worsening.
Beijing, Beijing MunicipalityAges 40 years+ - NCT04802707RecruitingPhase 2
Study drug for mitochondrial depletion disorder due to gene changes
This Phase 2 trial tests a treatment made from deoxynucleosides to help people with mitochondrial depletion disorder caused by certain gene changes. If you match the genetic diagnosis, the study may see whether the treatment improves symptoms or disease markers.
Montreal, QuebecAges 1 month–60 years - NCT06003283RecruitingPhase 4
Reducing rituximab doses in rheumatoid arthritis
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
Merksem, AntwerpenAges 18 years+ - NCT06088134Recruiting
Predicting survival after kidney cancer surgery with CT scans
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06653387Recruiting
Testing a new carotid stent with blood-flow reversal for high-risk patients
This trial tests a new carotid stent system used with a special blood-flow reversal device to treat blocked carotid arteries. It is for people with high-risk conditions who might not be good candidates for traditional open surgery, and aims to see if the stent is safe and effective in preventing strokes.
Sacramento, CaliforniaAges 18–79 - NCT06564571Recruiting
AI in endoscopic ultrasound study
This study is testing how well artificial intelligence can help doctors see and understand images from an endoscopic ultrasound. If you are scheduled for this procedure, you may be able to join.
Orlando, FloridaAges 18–100 - NCT07006649Recruiting
Study of blood flow in the eye for pseudoxanthoma elasticum
This study looks at blood flow in a layer of the eye called the choriocapillaris in people with pseudoxanthoma elasticum (PXE). It compares these findings with healthy volunteers to understand eye changes before they become severe.
AngersAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07010094Recruiting
Shockwave balloons for hardened heart artery blockages
This trial tests a special balloon that uses shock waves to crack calcium in heart arteries, making it easier to place a stent. It is for people with chest pain or signs of heart strain due to a single, severely blocked artery with dense calcium.
Fujian, XiamenAges 18–85 - NCT07006090Recruiting
Registry study of the Histolog Scanner in surgery
This study looks at how well the Histolog Scanner works during real surgeries. It helps doctors see tissue details right away, which may make surgery more precise.
GuildfordAges 18 years+ - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT07008469Enrolling by invitationPhase 3
Long-term safety study of del-desiran for DM1
This study tests whether the drug del-desiran continues to be safe and effective for people with DM1 (myotonic dystrophy type 1) after they complete an earlier study. You'll receive the drug and have regular check-ups to see how you're doing.
Los Angeles, CaliforniaAges 16 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT07012304RecruitingPhase 1/Phase 2
Testing gecacitinib for chronic graft-versus-host disease after 2 or more treatments
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
BeijingAges 18 years+ - NCT07007156Recruiting
Does a positive NECPAL score mean higher risk in the ICU?
This study looks at whether a specific tool, called NECPAL, can help predict if older adults in the ICU are more likely to have a higher risk of dying. NECPAL is a way to identify people who might benefit from extra support or palliative care.
Sant Pere de Ribes, BarcelonaAges 75 years+ - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,577 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.